As the market for bispecific antibody therapeutics continues to soar, novel solutions are required to overcome challenges in producing these next-generation molecules. In this presentation, our expert demonstrates how bYlok® uses a close-to-nature design solution to deliver high accurate heavy-light chain pairing efficiencies and improved manufacturability, with no observed effect on immunogenicity.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center